source
- STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting downRecent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.STAT · 13d ago↗ source
- Artiva to quit autoimmune cell therapy work, cut staff after patient deathsThe disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.BioPharma Dive · 14d ago↗ source
- After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforceArtiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include diss…